VA06 is a derivative of QS-21 that maintains strong adjuvant activity while significantly reducing toxicity. It can self-assemble into flexible worm-like micelles with continuous elongated nanostructures, enhancing drug encapsulation. VA06 induces antigen-specific antibody production, boosts the secretion of TNF-α, IFN-γ, and IL-2 in CD4+ and CD8+ T cells, and enhances the expression of immune-related and antiviral-related genes in mature dendritic cells. Without the need for liposomal formulations, VA06 simplifies production and storage processes. It is applicable for research on varicella-zoster virus infections and Mycobacterium tuberculosis infections.